All In Biotech

Drug Trial Radar · NCT03103568

A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers

An Open-label, Non-randomized, 2-arm, 2-period Fixed Sequence Phase 1 Study to Evaluate the Potential Inhibition of Nitisinone on Cytochrome P450 2C9, 2D6, and 2E1 and the Organic Anion Transporters OAT1 and OAT3 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Aug 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Mar 28, 2017

Primary completion

Jun 10, 2017

Study completion Jul 24, 2017

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label, non-randomized, 2-arm, 2-period fixed sequence phase 1 study to evaluate the potential inhibition of nitisinone on cytochrome P450 2C9, 2D6, and 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers

Conditions

  • Drug Drug Interaction

Interventions

  • Nitisinone in Arm ADrug

    4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.

  • TolbutamideDrug

    A 500 mg tablet is given as single oral dose 2 weeks apart.

  • MetoprololDrug

    A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.

  • ChlorzoxazoneDrug

    A 250 mg tablet is given as single oral dose 2 weeks apart.

  • FurosemideDrug

    A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.

  • Nitisinone in Arm BDrug

    4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve (AUC) infinity for CYP2C9 (tolbutamide) substrateTime frame: Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
  2. AUC infinity for CYP2D6 (metoprolol) substrateTime frame: Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
  3. AUC infinity for CYP2E1 (chlorzoxazone) substrateTime frame: Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
  4. AUC infinity for OAT1/OAT3 (furosemide) substrateTime frame: Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PAREXEL EPCU Berlin

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.